IGHE and asthma: Despite the large amount of data the new omics era has provided on type 2 high- and type 2 low-driven patterns of airway inflammation, the only biomarkers that are currently recommended in the The Global Initiative for Asthma (GINA) guidelines, as well as a recent ERS/ATS task force on the management of severe asthma to guide treatment with biologics, are total and/or specific serum IgE, blood eosinophils, and FeNO.